Patents by Inventor Alma Fulurija
Alma Fulurija has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10130704Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: GrantFiled: December 16, 2016Date of Patent: November 20, 2018Assignee: ONDEK PTY LTDInventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Publication number: 20170165357Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: ApplicationFiled: December 16, 2016Publication date: June 15, 2017Inventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Patent number: 9555104Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: GrantFiled: June 20, 2014Date of Patent: January 31, 2017Assignee: Ondek Pty LtdInventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Publication number: 20160175429Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: ApplicationFiled: June 20, 2014Publication date: June 23, 2016Inventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Patent number: 8992935Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.Type: GrantFiled: June 24, 2011Date of Patent: March 31, 2015Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
-
Patent number: 8790909Abstract: The present invention relates to strains of Helicobacter pylori useful for the delivery of biologically active agents. In particular, the present invention provides an isolated strain of H. pylori having: (a) low pathogenicity; (b) ability to naturally transform; and (c) ability to colonise mouse stomach mucosa without host adaptation.Type: GrantFiled: June 3, 2010Date of Patent: July 29, 2014Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Alma Fulurija, Wei Lu, Hans-Olof Nilsson, Barry J. Marshall
-
Patent number: 8715929Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.Type: GrantFiled: June 25, 2010Date of Patent: May 6, 2014Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Yakhya Dieye, Carola Schwann, Miriam Sehnal, Alma Fulurija, Barry J. Marshall
-
Publication number: 20130259888Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.Type: ApplicationFiled: June 24, 2011Publication date: October 3, 2013Applicant: ONDEK PTY LTDInventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
-
Publication number: 20120225454Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.Type: ApplicationFiled: June 25, 2010Publication date: September 6, 2012Applicant: ONDEK PTY LTDInventors: Mohammed Benghezal, Yakhya Dieye, Carola Schwann, Miriam Sehnal, Alma Fulurija, Barry J. Marshall
-
Publication number: 20120144509Abstract: The present invention relates to strains of Helicobacter pylori useful for the delivery of biologically active agents. In particular, the present invention provides an isolated strain of H. pylori having: (a) low pathogenicity; (b) ability to naturally transform; and (c) ability to colonise mouse stomach mucosa without host adaptation.Type: ApplicationFiled: June 3, 2010Publication date: June 7, 2012Inventors: Mohammed Benghezal, Alma Fulurija, Wei Lu, Hans-Olof Nilsson, Barry Marshall
-
Patent number: 7959924Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: GrantFiled: August 4, 2009Date of Patent: June 14, 2011Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20100143392Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: ApplicationFiled: August 4, 2009Publication date: June 10, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Patent number: 7572451Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of immunogens, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: GrantFiled: October 25, 2005Date of Patent: August 11, 2009Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20090028886Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus like particle (VLP) and at least one GnRH peptide or fragment or variant thereof linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of GnRH-related diseases and conditions and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: August 4, 2005Publication date: January 29, 2009Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F Bachmann, Alma Fulurija, Gary Jennings, Edwin Meijerink
-
Publication number: 20060088550Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: ApplicationFiled: October 25, 2005Publication date: April 27, 2006Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20050191317Abstract: The present invention provides ordered and repetitive antigen arrays comprising, inter alia, compositions comprising a virus-like particle (VLP) to which is linked at least one antigen, wherein said antigen is grehlin or peptides or fragments thereof. The invention also provides methods for producing the aforesaid compositions. The compositions and methods of the invention are useful in the production of vaccines and to efficiently induce self-specific immune responses, in particular antibody responses. The invention also provides for compositions and methods for the prevention and/or treatment of ghrelin-related conditions, disorders or diseases. For example, the compositions of the invention are useful in the production of vaccines for the prevention or treatment of obesity and other disease associated with increased food-uptake or increased body weight.Type: ApplicationFiled: January 19, 2005Publication date: September 1, 2005Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Alma Fulurija
-
Publication number: 20040076645Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a ghrelin or ghrelin-derived peptide-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one ghrelin or a ghrelin-derived peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of obesity and other disease associated with increased food-uptake or increased body weight and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: July 18, 2003Publication date: April 22, 2004Inventors: Martin F. Bachmann, Alma Fulurija